- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Pharmaceutical
Lilly CEO says he's not interested in Pfizer animal unit
October 5, 2011
Bloomberg NewsDrugmaker Eli Lilly and Co. doesn’t plan to buy Pfizer Inc.’s $3.58 billion animal-health business, CEO John Lechleiter
said Wednesday.
MoreEli Lilly, Turkish firm in talks to sell drugs in 26 nations
October 3, 2011
Bloomberg NewsEli Lilly and Co., the world’s biggest maker of psychiatric drugs, is in talks with Mustafa Nevzat Ilac Sanayii AS to
sell the Turkish company’s treatments in 26 countries, said Mustafa Nevzat’s CEO.
MoreLilly's Alimta get favorable opinion for new use in Europe
September 26, 2011
J.K. WallIf approved for continuation maintenance, Eli Lilly and Co.'s Alimta could be used for longer stretches in lung cancer patients,
generating more revenue.
MoreDebate rages over whether Lilly's Byetta lifts cancer risk
September 16, 2011
Bloomberg NewsA German researcher disputed the validity of a study that found Byetta and another diabetes drug increase cancer risk.
MoreHealth regulatory leaders ready to flock to city
September 14, 2011
IBJ StaffThe top event for regulatory professionals in the health care industry is headed to Indianapolis next month. The annual conference
of the Regulatory Affairs Professionals Society, or RAPS, is expected to draw thousands of members representing 120 companies
and organizations.
MoreFDA gets new report on Lilly diabetes drug
September 12, 2011
Associated PressDrugmakers Eli Lilly and Co. and Amylin Pharmaceuticals Inc. said Monday that patients taking their potential once-weekly
diabetes treatment, Bydureon, saw a significant improvement in cardiovascular risk factors.
MoreFDA deal with drugmakers raises user fees 6 percent
September 1, 2011
Bloomberg NewsDrugmakers including Eli Lilly an Co. have agreed with regulators on a 6-percent increase in review fees as part of reauthorizing
the drug-approval process through fiscal 2017.
MoreEndocyte completes secondary public offering
August 3, 2011
The West Lafayette-based biotech firm raised about $66.8 million by selling nearly 6.7 million shares of company stock, priced
at $12.26 per share.
MoreEli Lilly's Elanco unit blossoming at just the right time
July 30, 2011
Greg AndrewsAn investment firm projects that the Elanco animal-health business will generate sales of nearly $2 billion by 2012 and surpass
$3 billion by 2018.
MoreLilly wins appeals court ruling in Strattera patent case
July 29, 2011
Bloomberg NewsThe U.S. Court of Appeals for the Federal Circuit in Washington, D.C., overturned Friday a judge’s decision that Lilly’s
patent on attention-deficit treatment Strattera was invalid.
MoreDespite sales spike, Effient has middling prospects
July 25, 2011
J.K. WallRemember Effient? The blood thinner that was once Eli Lilly and Co.’s greatest post-Zyprexa hope and then, after a slow
launch, was dismissed as an abject failure? Well, it’s turning out to defy both predictions.
MoreUPDATE: Medco acquisition could lead to local consolidation
July 21, 2011
IBJ Staff and Bloomberg NewsIt’s not yet clear how Express Scripts Inc.’s $29.1 billion acquisition of rival Medco Health Solutions will affect
the companies’ central Indiana operations—or their 800-plus employees at two facilities here.
MoreLilly profit falls, but forecast rises after second quarter
July 21, 2011
J.K. WallSecond-quarter profit fell at Eli Lilly and Co., but the Indianapolis drugmaker beat the estimates of Wall Street analysts
by a penny per share and raised its full-year profit forecast by as much as 10 cents per share.
MoreLilly: Alzheimer's patients on failed drug didn’t improve
July 19, 2011
Bloomberg NewsEli Lilly and Co. said patients with Alzheimer’s disease whose conditions worsened upon taking the experimental drug
semagacestat didn’t improve after dosing was halted.
MoreFDA says potential diabetes drug may cause cancer
July 18, 2011
Bloomberg NewsDapagliflozin would be the first in a new class of diabetes treatments called SGLT2-inhibitors that work by letting patients
excrete excess blood sugar in their urine. Indianapolis-based Eli Lilly and Co. is among several companies pursuing similar
drugs.
MoreLilly's Cialis finally overtakes Viagra
July 11, 2011
J.K. WallWhy do drugmakers still pursue so many me-too drugs? Because, if marketed well, they can be extremely lucrative. Just ask
Eli Lilly and Co. about its drug Cialis.
MoreLechleiter: German drug pricing creates 'uncertainty' for Lilly
July 11, 2011
Bloomberg NewsEli Lilly & Co. CEO John C. Lechleiter said Germany’s overhaul of drug pricing lacked transparency and the new policy
creates “uncertainty” for the company’s business planning.
MoreTiming good for 2-in-1 biotech drugs
July 5, 2011
J.K. WallEli Lilly and Co.’s foray into combination drugs is well-timed because the company could take advantage of some the
world’s most successful biotech medicines, which are about to see their patents expire.
MoreR&D spending soars above value of new drugs
July 5, 2011
J.K. WallTo understand the depths of the pharmaceutical industry’s recent struggles, consider this: The industry has been spending
$57 billion more per year on research and development than the value of the products it has been launching. That’s a
problem.
MoreLilly asks judge to reject U.K. Zyprexa case
July 5, 2011
Bloomberg NewsEli Lilly and Co., the Indianapolis-based drugmaker whose best-selling schizophrenia medicine Zyprexa survived a patent challenge
in Britain two years ago, has asked a United Kingdom judge to reject a parallel lawsuit by a generic drug company.
MoreLilly plans 10 drugs in final-stage trials by year's end
June 30, 2011
Bloomberg NewsLilly has 33 drugs in the second and third stages of clinical trials, including medicines for cancer, diabetes and Alzheimer’s
disease, up from seven in 2005, the Indianapolis-based company said Thursday.
MoreLilly plans more investment in two-in-one drugs
June 28, 2011
J.K. WallIndianapolis-based drugmaker Eli Lilly on Tuesday will announce a multimillion-dollar investment to develop drugs that act
like two medicines in one. Lilly plans to add more scientists to back the effort.
MoreZyprexa appeal rejected by Supreme Court
June 27, 2011
Bloomberg NewsThe U.S. Supreme Court has refused to revive a bid to press a $6.8 billion class-action suit against Eli Lilly and Co. over
the marketing of Zyprexa, the company’s schizophrenia treatment.
MoreLilly, partner find no Bydureon effect on heart rhythm
June 27, 2011
Bloomberg NewsEli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. said an analysis of a 148-patient trial found no evidence
that their experimental Bydureon diabetes drug causes prolonged heart rhythms.
MoreLilly diabetes pill recommended for EU approval
June 24, 2011
Bloomberg NewsEli Lilly and Co. and Boehringer Ingelheim GmbH’s Trajenta medicine for Type 2 diabetes has been recommended for approval
in Europe, putting the drug on track to enter the region’s market this year.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
We loved lakehouse and think the Arbor Village would be a great location. It is less than 2 miles from over 1000 rooftops in the 225,000 to over 1 million range. Many people could use the great fishers trail system to bike or walk there. Just an idea Scotty -- but maybe something closer to 3 Wiseman would good. The only microbrew in area is Ram (boring)
True, it's an ESPN production, but ESPN is just another name for ABC Sports, or what used to be ABC Sports since ABC Sports no longer exists as a name. ESPN=ABC Sports= ESPN. ESPN is, according to Forbes "the world's most valuable media property" worth $40 billion. Despite that, they fired 400 people this week.
The Prestige was a great flick.
Larry - even though the race is on ABC, ESPN does all of the work, so that is why ESPN is mentioned. Most sports on ABC are called something like "ESPN on ABC."
My oldest daughter graduated from IU with a Secondary Education degree. She graduated with honors and spent 3 years trying to find a teaching job in Indiana. Many of her fellow education degree graduates still don't have teaching jobs. As schools downsize and cut budgets, less teaching jobs are available. I'm not sure I see why we feel the need to bring more teachers to Indiana.